Advertisement

CEN Case Reports

, Volume 8, Issue 1, pp 1–7 | Cite as

Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia

  • Akihiro Tsuchimoto
  • Yuta Matsukuma
  • Kenji Ueki
  • Takehiro Nishiki
  • Atsushi Doi
  • Yasuhiro Okabe
  • Masafumi Nakamura
  • Kazuhiko Tsuruya
  • Toshiaki NakanoEmail author
  • Takanari Kitazono
  • Kosuke Masutani
Case Report
  • 82 Downloads

Abstract

Thrombotic microangiopathy (TMA) develops from various etiologies, and it is often difficult to distinguish the etiology of TMA in kidney transplantation. Antiphospholipid syndrome (APS) is one of the differential diagnoses for TMA that may cause acute loss of graft function or fatal thrombotic complications. This report details a 66-year-old male patient with polycythemia after ABO-incompatible kidney transplantation. Antibody screening tests were negative before transplant. Despite administration of an adequate desensitization therapy including plasmapheresis and rituximab, he developed acute graft dysfunction on postoperative day 112 and graft biopsy revealed prominent microvascular inflammation in the glomerular capillaries without immunoglobulin deposits. Flow cytometric panel-reactive antibody screening failed to detect donor-specific antibodies at both pre-transplant and episode biopsies. Anticardiolipin antibody was repeatedly positive, but neither thrombosis nor previous thrombotic episodes were detected. After excluding several differential diagnoses, the graft dysfunction with unexplained TMA was treated with steroid pulse, plasmapheresis and rituximab re-induction. Anticardiolipin antibody disappeared after this intensive treatment and graft function recovered gradually and stabilized for 52 months. This report suggests that asymptomatic anticardiolipin antibody may be associated with acute graft dysfunction. Even if thrombotic episodes are not observed, an exist of anticardiolipin antibody may be one of the risk factors of renal TMA after kidney transplantation.

Keywords

Living-donor Antiphospholipid syndrome Myeloproliferative disorders Rituximab Plasma exchange Plasmapheresis Graft biopsy 

Abbreviations

APS

Antiphospholipid syndrome

β2GPI

β2glycoprotein I

TMA

Thrombotic microangiopathy

Notes

Acknowledgements

We thank Gillian Campbell, PhD, from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript.

Author contributions

TA participated in planning this research and data collection, MK, MY and UK analyzed the renal pathology, NT and DA participated in data collection, and YO, NM, TK, NT, and KT participated in the management of this research. All authors contributed to the writing of the manuscript.

Funding

Honoraria Takanari Kitazono (Bayer Pharmaceutical Co., Bristol-Myers Squibb Co., Daiichi-Sankyo Co.), Kazuhiko Tsuruya (Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co.). Donations Takanari Kitazono (Astellas Pharma Inc., Daiichi-Sankyo Co., Eisai Co., Kyowa Hakko Kirin Co., Mitsubishi Tanabe Pharma Co., MSD K.K., Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Sanofi-Aventis Pharmaceutical Co., Takeda Pharmaceutical Co.), Kazuhiko Tsuruya (Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Otsuka Pharmaceutical Co., Takeda Pharmaceutical Co.). Endowed department Kazuhiko Tsuruya (Baxter).

Compliance with ethical standards

Ethics

The clinical and research activities of the study were consistent with the principles of the Declaration of Istanbul, as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Informed consent was acquired from the participant included in the study.

Conflict of interest

The authors have no conflict of interest to declare.

Research involving human participants

Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number #24–54) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kawaguchi K, Kawanishi K, Sato M, Itabashi M, Fujii A, Kanetsuna Y, et al. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation. Nephrology (Carlton). 2015;20(Suppl 2):61–5.CrossRefGoogle Scholar
  2. 2.
    Meehan SM, Kremer J, Ali FN, Curley J, Marino S, Chang A, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol. 2011;6:395–403.CrossRefGoogle Scholar
  3. 3.
    Takeda A, Ohtsuka Y, Horike K, Inaguma D, Goto N, Watarai Y, et al. A case of tacrolimus-associated thrombotic microangiopathy after ABO-blood-type-incompatible renal transplantation. Clin Transplant. 2011;25(Suppl 23):15–8.CrossRefGoogle Scholar
  4. 4.
    Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transpl. 2010;10:1804–11.CrossRefGoogle Scholar
  5. 5.
    Mondragon-Ramirez G, Bochicchio T, Garcia-Torres R, Amigo MC, Martinez-Lavin M, Reyes P, et al. Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS). Clin Transpl. 1994;8:93–6.Google Scholar
  6. 6.
    Baid S, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10:146–53.Google Scholar
  7. 7.
    Chew CG, Bannister KM, Mathew TH, Russ G. Seymour A. Thrombotic microangiopathy related to anticardiolipin antibody in a renal allograft. Nephrol Dial Transpl. 1999;14:436–8.CrossRefGoogle Scholar
  8. 8.
    Erkan D, Leibowitz E, Berman J. Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843–9.Google Scholar
  9. 9.
    Ruffatti A, Marson P, Valente M, Ciprian M, Tonello M, Marchini F, et al. Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation. Transpl Int. 2007;20:475–7.CrossRefGoogle Scholar
  10. 10.
    Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transpl. 2011;11:2523–7.CrossRefGoogle Scholar
  11. 11.
    Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noel LH, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transpl. 2013;13:2179–85.CrossRefGoogle Scholar
  12. 12.
    Barbour TD, Crosthwaite A, Chow K, Finlay MJ, Better N, Hughes PD, et al. Antiphospholipid syndrome in renal transplantation. Nephrology (Carlton). 2014;19:177–85.CrossRefGoogle Scholar
  13. 13.
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311.CrossRefGoogle Scholar
  14. 14.
    Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14:401–14.CrossRefGoogle Scholar
  15. 15.
    Hughson MD, Nadasdy T, McCarty GA, Sholer C, Min KW. Silva F. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis. 1992;20:150–8.CrossRefGoogle Scholar
  16. 16.
    Levine JS, Branch DW. Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–63.CrossRefGoogle Scholar
  17. 17.
    Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL. Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41:471–9.CrossRefGoogle Scholar
  18. 18.
    Okamoto M, Koshino K, Sakai K, Nobori S, Matsuyama M, Ushigome H, et al. A case of recurrent focal segmental glomerulosclerosis (FSGS) involving massive proteinuria (> 50 g/day) immediately after renal transplantation. Clin Transpl. 2011;25(Suppl 23):53–8.CrossRefGoogle Scholar
  19. 19.
    Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80:753–9.CrossRefGoogle Scholar
  20. 20.
    Meroni PL, Chighizola CB, Rovelli F. Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16:209.CrossRefGoogle Scholar
  21. 21.
    Bienaime F, Legendre C, Terzi F. Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017;91:34–44.CrossRefGoogle Scholar
  22. 22.
    Seshan SV, Franzke CW, Redecha P, Monestier M, Mackman N. Girardi G. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood. 2009;114:1675–83.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Akihiro Tsuchimoto
    • 1
  • Yuta Matsukuma
    • 1
  • Kenji Ueki
    • 1
  • Takehiro Nishiki
    • 2
  • Atsushi Doi
    • 3
  • Yasuhiro Okabe
    • 3
  • Masafumi Nakamura
    • 3
  • Kazuhiko Tsuruya
    • 1
  • Toshiaki Nakano
    • 1
    • 4
    Email author
  • Takanari Kitazono
    • 1
  • Kosuke Masutani
    • 5
  1. 1.Department of Medicine and Clinical Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of SurgeryFukuoka Red Cross HospitalFukuokaJapan
  3. 3.Department of Surgery and OncologyKyushu UniversityFukuokaJapan
  4. 4.Department of Integrated Therapy for Chronic Kidney DiseaseKyushu UniversityFukuokaJapan
  5. 5.Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of MedicineFukuoka UniversityFukuokaJapan

Personalised recommendations